Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

Stoke Therapeutics Builds Commercial Infrastructure as Clinical Catalysts Approach

Stoke Therapeutics is expanding market-access teams while two data readouts approach, but preparation is not proof of approval or commercial…

Nov 15, 2026
Pharmaceutical

Cocrystal Pharma’s Widening Loss Meets Fresh OPKO Backing and Norovirus Trial Progress

Nasdaq-listed COCP reported a wider $3.44 million quarterly loss alongside Phase 1b progress and a $5 million OPKO investment.

Nov 15, 2026
Pharmaceutical

Viking Therapeutics Takeover Chatter Puts VKTX Back in the M&A Spotlight

Renewed takeover interest lifted VKTX shares, sharpening the debate over obesity-drug consolidation and the risks of M&A-driven repricing.

Nov 14, 2026
Pharmaceutical

Sellas Life Sciences Surges 17% Ahead of Potentially Transformative AML Data

Sellas Life Sciences shares jumped 17% after hours as investors positioned for the company’s expected Phase 3 AML readout this month.

Nov 13, 2026
Pharmaceutical

Candel Therapeutics Target Cut to $19 as BLA Delay Raises Regulatory Risk

Stifel cut Candel Therapeutics’ target to $19 after a BLA delay, while the biotech continues FDA discussions and readiness work.

Nov 13, 2026
Pharmaceutical

Rezolute Stock Jumps 7.8% as Tumor Hypoglycemia Data Set Up FDA Catalyst

Rezolute shares rose 7.8% pre-market after tumor hypoglycemia data, with FDA discussions planned for Q1 2027 as topline results remain pendi…

Nov 13, 2026
Pharmaceutical

Denali Therapeutics Gets Bullish Wells Fargo Initiation on Hunter Syndrome Drug

Wells Fargo initiated Denali Therapeutics at overweight, putting fresh sell-side attention on its approved Hunter Syndrome therapy, Avlayah.

Nov 13, 2026
Pharmaceutical

Altimmune’s Wider Q3 Loss Puts the Spotlight on Its $480 Million Clinical Runway

Altimmune’s wider Q3 loss sharpens the balance-sheet debate as $480 million supports pemvidutide’s ongoing liver-disease trials.

Nov 12, 2026
Pharmaceutical

FDA Fast-Track Shutdown Raises Approval-Timeline Risks for Biotech Investors

The reported end of the FDA Fast-Track program could lengthen approval timelines, while SPY valuation reportedly remained steady.

Nov 12, 2026
Pharmaceutical

Biotech Traders Face a Year-End Wave of FDA Catalysts for BBIO and VRTX

Priority reviews for BBIO and VRTX create a concentrated late-2026 FDA calendar spanning muscle disease, kidney disease, cancer, pain and ep…

Nov 12, 2026
Pharmaceutical

CanaRx Arrests Put Cross-Border Prescription Drug Importation Under the Microscope

The arrests of two CanaRx officials sharpen questions about U.S.-Canada drug trade, discount pricing models and regulatory oversight.

Nov 12, 2026
Pharmaceutical

ImmunityBio Stock Faces a Sentiment Test as Anktiva Catalysts Collide With a Sharp Weekly Selloff

IBRX is on pace for its worst week in nearly two years even as Anktiva gains a broader approval and a year-end FDA filing approaches.

Nov 12, 2026